Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial.
- 1Department Pharmaceutical Biotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.
- 2Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, Iran.
Abstract
Introduction
Given the proven cardiovascular benefits of Empagliflozin (EM), we aimed to investigate the effect of Empagliflozin on Cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) expressions in circulating monocytes in type 2 diabetic patients after MI.Methods
This randomized, double-blind, placebo-controlled study included 33 patients referred to Ayatollah Mousavi Hospital in Zanjan between 5 of September to 25 of December, 2024. Eligible patients with type 2 diabetes and MI who underwent primary percutaneous coronary intervention (PCI) were randomly assigned (17:16) to receive either 10 mg of EMPA daily or placebo for 12 weeks. Target genes expression levels were quantified by real time PCR, and data were analyzed by SPSS version 26.Results
Thirty-three patients were included in this study (mean age: 61.27±9.07, 66% male), mean diabetes duration was longer in intervention group (7.82±5.13) compared to placebo group (3.75±2.74), hypertension was the most common comorbidity (57%). CTF-1 expression in the intervention group was 0.3±0.28 and in placebo group was 5.66±6.52. GDF-15 expression in the intervention group was 0.198±0.22 and in placebo group was 1.66±1.04. EMPA significantly reduced expression of CTF-1 (13-fold) (P=0.003) and GDF-15 (7-fold) (P ˂ 0.0001). The CTF-1 and GDF-15 expression reduction were not associated with any other clinical variables. Significant reduction observed in LDL (P=0.045) and triglycerides (P=0.013) after intervention.Conclusion
EMPA significantly reduced the expression of CTF-1 and GDF-15 in type 2 diabetic, post MI patients, which are associated with atherosclerosis, and suggest that potential anti-atherosclerotic effect of EMPA mediated through modulation of GDF-15 and CTF-1 gene expression.
Related
- Association Between Admission Calculated Serum Osmolality and New-Onset Atrial Fibrillation in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
- Comparison of treatment delays and in-hospital outcomes between self-transported and EMS-transported patients with ST-segment elevation myocardial infarction undergoing PCI
- Triglyceride-glucose index and risk of major adverse cardiovascular events in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention
- Association of FIB-4 and APRI with Contrast-Associated Acute Kidney Injury in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Coronary Angiography
- Association of Platelet–Albumin–Bilirubin and Albumin–Bilirubin Scores with Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI
BibTeX
@article{rastgoo2026impact,
title = {{Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial.}},
author = {Reza Rastgoo and Mahnaz Yousefi Ramandi and Fereshteh Ebrahimi and Reza Madadi and Hamid Khederlou and Ali Ramazani},
journal = {Journal of cardiovascular and thoracic research},
year = {2026},
month = jun,
doi = {10.34172/jcvtr.33675},
url = {https://europepmc.org/article/MED/42898280},
note = {CC BY},
}
RIS
TY - JOUR
TI - Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial.
AU - Reza Rastgoo
AU - Mahnaz Yousefi Ramandi
AU - Fereshteh Ebrahimi
AU - Reza Madadi
AU - Hamid Khederlou
AU - Ali Ramazani
PY - 2026
DA - 2026/06/30
JO - Journal of cardiovascular and thoracic research
DO - 10.34172/jcvtr.33675
UR - https://europepmc.org/article/MED/42898280
AB - Introduction Given the proven cardiovascular benefits of Empagliflozin (EM), we aimed to investigate the effect of Empagliflozin on Cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) expressions in circulating monocytes in type 2 diabetic patients after MI.Methods This randomized, double-blind, placebo-controlled study included 33 patients referred to Ayatollah Mousavi Hospital in Zanjan between 5 of September to 25 of December, 2024. Eligible patients with type 2 diabetes and MI who underwent primary percutaneous coronary intervention (PCI) were randomly assigned (17:16) to receive either 10 mg of EMPA daily or placebo for 12 weeks. Target genes expression levels were quantified by real time PCR, and data were analyzed by SPSS version 26.Results Thirty-three patients were included in this study (mean age: 61.27±9.07, 66% male), mean diabetes duration was longer in intervention group (7.82±5.13) compared to placebo group (3.75±2.74), hypertension was the most common comorbidity (57%). CTF-1 expression in the intervention group was 0.3±0.28 and in placebo group was 5.66±6.52. GDF-15 expression in the intervention group was 0.198±0.22 and in placebo group was 1.66±1.04. EMPA significantly reduced expression of CTF-1 (13-fold) (P=0.003) and GDF-15 (7-fold) (P ˂ 0.0001). The CTF-1 and GDF-15 expression reduction were not associated with any other clinical variables. Significant reduction observed in LDL (P=0.045) and triglycerides (P=0.013) after intervention.Conclusion EMPA significantly reduced the expression of CTF-1 and GDF-15 in type 2 diabetic, post MI patients, which are associated with atherosclerosis, and suggest that potential anti-atherosclerotic effect of EMPA mediated through modulation of GDF-15 and CTF-1 gene expression.
SN - 2008-5117
SN - 2008-6830
ER -